Zhejiang Jolly Pharmaceutical Co.,LTD

XSEC:300181 Stock Report

Market Cap: CN¥11.4b

Zhejiang Jolly PharmaceuticalLTD Past Earnings Performance

Past criteria checks 5/6

Zhejiang Jolly PharmaceuticalLTD has been growing earnings at an average annual rate of 45%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 20.4% per year. Zhejiang Jolly PharmaceuticalLTD's return on equity is 19.9%, and it has net margins of 20.5%.

Key information

45.0%

Earnings growth rate

42.3%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate20.4%
Return on equity19.9%
Net Margin20.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Zhejiang Jolly PharmaceuticalLTD makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XSEC:300181 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,52251898272
30 Jun 242,35948195778
31 Mar 242,12042892676
31 Dec 231,94238387579
30 Sep 231,92635689072
30 Jun 231,92233692973
31 Mar 231,86130292771
01 Jan 231,80527392764
30 Sep 221,72325290864
30 Jun 221,65522887461
31 Mar 221,55720483750
01 Jan 221,45717979546
30 Sep 211,40015874542
30 Jun 211,32214571933
31 Mar 211,23812267831
31 Dec 201,0918960230
30 Sep 201,0244959730
30 Jun 209492955530
31 Mar 209012653029
31 Dec 199112652927
30 Sep 198593449926
30 Jun 197671444527
31 Mar 197642343226
31 Dec 187302141327
30 Sep 186092040722
30 Jun 186293138833
31 Mar 186474338527
31 Dec 176794538321
30 Sep 178044937817
30 Jun 17814633960
31 Mar 17830594160
31 Dec 16840724240
30 Sep 16819864100
30 Jun 16810874130
31 Mar 16720853730
31 Dec 15671853630
30 Sep 156571033610
30 Jun 156201113490
31 Mar 155721073300
31 Dec 145151033120
30 Sep 14457943010
30 Jun 14440902970
31 Mar 14431852930
31 Dec 13419812850

Quality Earnings: 300181 has high quality earnings.

Growing Profit Margin: 300181's current net profit margins (20.5%) are higher than last year (18.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300181's earnings have grown significantly by 45% per year over the past 5 years.

Accelerating Growth: 300181's earnings growth over the past year (45.4%) exceeds its 5-year average (45% per year).

Earnings vs Industry: 300181 earnings growth over the past year (45.4%) exceeded the Pharmaceuticals industry -2.5%.


Return on Equity

High ROE: 300181's Return on Equity (19.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies